Partner with Market Access, Government Pricing, Commercial Operations, and FP&A to validate contract terms, pricing, and utilization data, and to provide GTN forecasts, trend analyses, and channel inventory insights that inform business decisions; leverage deep industry knowledge to anticipate GTN trends and risks, and share expertise to build revenue and GTN knowledge across Finance and Commercial partners. Zenas' earlier stage programs include ZB021, a clinical-stage, potentially best-in-class, oral, IL-17AA/AF inhibitor; ZB022, a preclinical, potentially best-in-class, oral, brain-penetrant, TYK2 inhibitor; and ZB014, a preclinical half-life extended anti-CD-19 and FcRIIb monoclonal antibody.